Temporal trends in non-Burkitt non-Hodgkin lymphoma–related mortality in the United States over the last three decades: An analysis of the Global Burden of Disease database.

e19076 Background: Non-Burkitt non-Hodgkin lymphoma (NHL) is a significant hematologic malignancy with considerable morbidity and mortality in the United States. Analyzing mortality trends over the past decades provides insight into the impact of advancements in diagnosis and treatment. Methods: Mortality data, including age-standardized mortality rate, for non-Burkitt NHL in the United States from 1990 to 2019 were extracted from the Global Burden of Disease database. Temporal trends were analyzed using Joinpoint regression analysis by calculating the Annual Percentage Change (APC) and Average Annual Percentage Change (AAPC). Results: An estimated total of 780,363 deaths were reported due to non-Burkitt NHL during the study period. Overall Trends: Mortality rates initially increased (APC: 2.00 from 1990–1995; p < 0.001), followed by a non-significant decline (APC: -0.48 from 1995–1998; p > 0.05). A significant decline was noted from 1998 to 2007 (APC: -3.06; p < 0.001), and a continued decline from 2007 to 2019 (APC: -1.97; p < 0.001). The overall AAPC for the period was -1.49 (95% CI: -1.52 to -1.44; p < 0.001). Gender-Specific Trends: Females: Mortality increased initially (APC: 2.18 from 1990–1995; p < 0.001), followed by stabilization and subsequent declines (APC: -3.58 from 1999–2004; p < 0.001, APC: -2.15 from 2010–2019; p < 0.001). The overall AAPC for females was -1.57 (95% CI: -1.61 to -1.53; p < 0.001). Males: Mortality exhibited an early rise (APC: 1.89 from 1990–1995; p < 0.001), followed by declines in later years (APC: -1.78 from 2007–2019; p < 0.001). The overall AAPC for males was -1.40 (95% CI: -1.48 to -1.39; p < 0.001). Conclusions: Mortality due to non-Burkitt NHL in the United States has significantly declined over the past three decades, likely reflecting improvements in therapeutic approaches and early detection strategies. The observed gender differences highlight the need for tailored interventions to further reduce mortality and improve patient outcomes.